Droxidopa Capsule
Product Images NDC 72205-072

9 FDA label images from Novadoz Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Droxidopa (NDC 72205-072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Droxidop-capsules100-mg-500s-label (Droxidop Capsules100 mg 500s Label)

Droxidop-capsules100-mg-500s-label (Droxidop Capsules100 mg 500s Label)
Droxidopa Capsules 100 mg label for oral administration, showing 500 capsules per container. The label includes storage instructions, warnings, and manufacturer information: Manufactured by MSN Laboratories Private Limited, India, and distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. The label displays Rx Only designation and barcode.*
FDA Label Image

Droxidop-capsules100-mg-90s-label (Droxidop Capsules100 mg 90s Label)

Droxidop-capsules100-mg-90s-label (Droxidop Capsules100 mg 90s Label)
Label for Droxidopa Capsules 100 mg in a 90-capsule bottle. The label includes storage instructions, warnings, manufacturer MSN Laboratories Private Limited, and distributor Novadoz Pharmaceuticals LLC. It features barcodes and a designation for Rx only, with a prominent display of the 100 mg strength and the Novadoz logo.*
FDA Label Image

Droxidop-capsules200-mg-500s-label (Droxidop Capsules200 mg 500s Label)

Droxidop-capsules200-mg-500s-label (Droxidop Capsules200 mg 500s Label)
Label for Droxidopa Capsules 200 mg, oral dosage form, containing 500 capsules. The label shows the proprietary name Droxidopa, strength 200 mg in a prominent orange box, and details including storage instructions, manufacturer (MSN Laboratories Private Limited, India), and distributor (Novadoz Pharmaceuticals LLC, Piscataway, NJ). It includes barcode and prescription-only designation.*
FDA Label Image

Droxidop-capsules200-mg-90s-label (Droxidop Capsules200 mg 90s Label)

Droxidop-capsules200-mg-90s-label (Droxidop Capsules200 mg 90s Label)
Droxidopa 200 mg capsules label displaying the product name and strength prominently. The label includes storage instructions, warnings, manufacturer (MSN Laboratories Private Limited, India), and distributor details (Novadoz Pharmaceuticals LLC, Piscataway, NJ). The package contains 90 capsules and features a barcode on the right side.*
FDA Label Image

Droxidop-capsules300-mg-500s-label (Droxidop Capsules300 mg 500s Label)

Droxidop-capsules300-mg-500s-label (Droxidop Capsules300 mg 500s Label)
Label for Droxidopa Capsules 300 mg by Novadoz Pharmaceuticals LLC. The label states each capsule contains 300 mg of droxidopa. It includes storage instructions, warning to keep out of reach of children, and manufacturer information (MSN Laboratories Private Limited, India). The package contains 500 capsules and includes barcodes and contact information.*
FDA Label Image

Droxidop-capsules300-mg-90s-label (Droxidop Capsules300 mg 90s Label)

Droxidop-capsules300-mg-90s-label (Droxidop Capsules300 mg 90s Label)
Label for Droxidopa Capsules 300 mg oral capsules, containing 90 capsules per container. The label indicates the product is Rx only, manufactured by MSN Laboratories Private Limited, and distributed by Novadoz Pharmaceuticals LLC. Storage instructions and warnings about the capsule seal and keeping out of reach of children are included, along with barcode and contact information.*
FDA Label Image

Figure-2 (Droxidopa Figre 02)

Figure-2 (Droxidopa Figre 02)
A bar chart comparing the percentage of subjects reporting improvement in OHSA Question 1 between placebo and Droxidopa groups. The x-axis shows improvement scores from -8 (worse) to 8 (better), and the y-axis indicates the percent of subjects. Black bars represent Droxidopa and white bars represent placebo results across improvement levels.*
FDA Label Image

Figure-01 (Droxidopa Figure 01)

Figure-01 (Droxidopa Figure 01)
A line graph showing the mean change in dizziness over eight weeks during a double-blind treatment phase comparing Droxidopa and Placebo groups. The Y-axis represents mean change in dizziness, and the X-axis shows weeks. Data points with error bars indicate changes, with Droxidopa showing a greater decrease in dizziness compared to Placebo, particularly within the first week.*
FDA Label Image

Structure (Droxidopa Structure)

Structure (Droxidopa Structure)
Chemical structure of the active ingredient Droxidopa showing its molecular arrangement including hydroxyl (OH), amino (NH2), and carboxyl (COOH) groups attached to a benzene ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.